Please ensure Javascript is enabled for purposes of website accessibility

Why Shares of Geron Corp. Cratered in January

By George Budwell - Feb 11, 2016 at 4:19PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Geron's stock got clobbered by the moody market last month.

GERN Chart

What: Shares of the clinical-stage oncology company Geron Corp. (GERN 4.38%) shed nearly 40% of their value last month, according to data provided by S&P Global Market Intelligence. Fortunately, this drastic sell-off didn't stem from a clinical or regulatory setback for the drugmaker -- but rather it appears simply to be the result of the market's change of heart toward all biotechs, especially risky development-stage companies like Geron. 

So what: Geron is perhaps the poster child for high-risk/high-reward clinical-stage biotechs. After all, the biotech has put all of its weight behind developing a single drug following its restructuring process that started in 2011. This drug is a telomerase inhibitor called imetelstat that has the potential to be a truly disease-modifying treatment for deadly blood disorders such as myelofibrosis and myelodysplastic syndrome. As the market seemingly lost its appetite for risk altogether, though, it's not surprising this risky small-cap biotech hit the skids in January. 

Now what: Unfortunately, Geron may not be able to break out of this funk anytime soon. Going forward, the next major set of catalysts that could drive shares higher are the top-line data readouts from imetelstat's ongoing clinical trials for myelofibrosis and myelodysplastic, and these trials probably won't produce anything of note until at least the fourth-quarter of this year.

Turning to the big picture, Geron does have a rather favorable licensing deal in place with Johnson & Johnson (JNJ 0.11%) for imetelstat that could trigger milestone payments of nearly $1 billion in total -- that is, if the drug continues down the road of turning into a truly game-changing treatment for myelofibrosis and possibly other blood-based disorders as well. As Johnson & Johnson has an almost uncanny ability of spotting promising cancer drugs early in their development, I think Geron does present a compelling value proposition for seasoned biotech investors that truly understand the significant risks involved.


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Geron Corporation Stock Quote
Geron Corporation
$1.43 (4.38%) $0.06
Johnson & Johnson Stock Quote
Johnson & Johnson
$182.49 (0.11%) $0.20

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.